NCT07581834招募中2 期
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 2,000
- 试验地点
- 2
研究概览
简要总结
This study is a multicenter, prospective, randomized, open-label clinical study to assess the efficacy and safety of endocrine combined with different doses and treatment duration of darisenatide adjuvant therapy in HR +/HER2- early breast cancer. The study planned to include 2000 HR +/HER2- early breast cancer patients who met the study criteria and were randomized in a 1:1 ratio to Column 1 and Column 2 stratified by nodal status (positive/negative), prior (neo) adjuvant chemotherapy (yes/no), and clinical/pathological stage (Stage II/III).
Cohort 1 received dalcili 125 mg in combination with endocrine therapy for 2 years with dalcili; Cohort 2 received dalcili 100 mg in combination with endocrine therapy for 3 years with dalcili; treatment had to be discontinued until disease progression, intolerable adverse events, withdrawal of consent, or investigator judgment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female aged 18 years or older with breast cancer who are postmenopausal or premenopausal/perimenopausal.
- •Patients with early-stage breast cancer whose HR status is positive and HER2 status is negative, as confirmed by histology (immunohistochemistry showing ER ≥10% and/or PR ≥10%, HER2 0-1+ or HER2 ++ but negative by FISH or CISH testing, with no amplification).
- •Patients with histologically confirmed invasive breast cancer at clinical/pathological stages II-III.
- •Note: For stage IIA, N1 is required, or N0 with Grade 3 or Grade 2 tumors combined with high-risk factors such as Ki-67 ≥20% or positive genetic testing (including but not limited to high-risk results in the 21-gene test). If the patient has previously received neoadjuvant therapy, the clinical stage at the time before neoadjuvant therapy must meet the above criteria.
- •Patients who have previously received or not received neoadjuvant chemotherapy or adjuvant chemotherapy are eligible to enroll.
- •The time interval from surgery to enrollment must not exceed 12 months.
- •Patients who have received radiotherapy must have recovered from the acute effects of radiotherapy, and there must be at least 14 days of washout period from the end of radiotherapy to enrollment.
- •Patients who have previously received chemotherapy must have recovered from the acute adverse effects of chemotherapy before enrollment ([CTCAE] grade ≤1), except for hair loss or grade 2 peripheral neuropathy.There must be a washout period of at least 21 days between the last administration of chemotherapy and enrollment in the study.
- •The Eastern Cooperative Oncology Group performance status score must be 0-
- •The functions of major organs must meet the following requirements: a) Blood tests: neutrophils (ANC) ≥1.5×10^9/L; platelet count (PLT) ≥90×10^9/L; hemoglobin (Hb) ≥90 g/L. b) Blood biochemistry tests: total bilirubin (TBIL) ≤2.5×ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×ULN; alkaline phosphatase ≤2.5×ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN. c) 12-lead electrocardiogram: QT interval corrected using the Fridericia method (QTcF) < 470 ms in females (QTcF calculation formula: QTcF = QT/(RR^1/3)). Participants must voluntarily agree to participate in the study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with follow-up assessments.
排除标准
- •Stage IV breast cancer or recurrent/metastatic breast cancer, or inflammatory breast cancer;
- •A history of any malignant tumor, or previous receipt of anti-tumor therapy or radiotherapy for any malignant tumor, excluding cured cases of cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma, etc.
- •Participating in other clinical trials simultaneously;
- •Received a blood transfusion within 2 weeks prior to enrollment, or received treatments such as colony-stimulating factors;
- •Individuals with a known history of allergy to any component of this medication;
- •A history of immunodeficiency, including a positive HIV test result, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
- •Any history of heart disease, including: (1) angina pectoris; (2) arrhythmias that require medical treatment or are clinically significant; (3) myocardial infarction; (4) heart failure; (5) any other heart disease deemed by the study investigators to be inappropriate for participation in this trial.
- •Pregnant or lactating female patients;
- •Any other circumstances in which the researchers deem the participant unsuitable for participating in this study.
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentBreast CancerNCT07467330Fujian Cancer Hospital258
尚未招募
3 期
Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast CancerBreast Cancer2024-513540-29-00Alliance Foundation Trials LLC303
已完成
3 期
Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.Pain ManagementOsteoarthritisNCT07549386Laboratorios Liomont123
招募中
4 期
A study to allow continued access to ribociclibCTRI/2024/08/072213Novartis Healthcare Pvt Ltd137
Enrolling By Invitation
2 期
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerNCT07441369Fudan University16